BioMarin Pharmaceutical Inc.
BMRN
$65.91
$0.841.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 989.71M | 766.21M | 874.57M | 776.13M | 825.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 989.71M | 766.21M | 874.57M | 776.13M | 825.41M |
| Cost of Revenue | 398.05M | 373.80M | 348.91M | 549.56M | 311.40M |
| Gross Profit | 591.66M | 392.41M | 525.65M | 226.57M | 514.01M |
| SG&A Expenses | 308.73M | 249.98M | 324.16M | 268.42M | 232.28M |
| Depreciation & Amortization | 73.49M | 4.48M | 4.85M | 4.85M | 4.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 780.27M | 628.26M | 677.92M | 822.83M | 548.52M |
| Operating Income | 209.44M | 137.95M | 196.64M | -46.69M | 276.89M |
| Income Before Tax | 61.38M | 141.20M | -27.15M | -26.32M | 297.87M |
| Income Tax Expenses | 16.62M | 35.68M | 19.42M | 4.42M | 57.34M |
| Earnings from Continuing Operations | 44.76M | 105.53M | -46.57M | -30.74M | 240.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.76M | 105.53M | -46.57M | -30.74M | 240.53M |
| EBIT | 209.44M | 137.95M | 196.64M | -46.69M | 276.89M |
| EBITDA | 307.08M | 154.36M | 209.68M | -28.21M | 295.45M |
| EPS Basic | 0.23 | 0.55 | -0.24 | -0.16 | 1.25 |
| Normalized Basic EPS | 0.52 | 0.49 | 0.70 | -0.09 | 0.97 |
| EPS Diluted | 0.23 | 0.54 | -0.24 | -0.16 | 1.23 |
| Normalized Diluted EPS | 0.51 | 0.47 | 0.70 | -0.09 | 0.94 |
| Average Basic Shares Outstanding | 193.42M | 192.50M | 192.23M | 192.03M | 191.91M |
| Average Diluted Shares Outstanding | 194.47M | 197.67M | 192.23M | 192.03M | 197.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |